This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
Arcadia Biosciences (RKDA) Gets a Buy from Lake Street
Lake Street analyst Ben Klieve maintained a Buy rating on Arcadia Biosciences (RKDA – Research Report) today and set a price target of $12.00. The company’s shares closed yesterday at $4.29.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
According to TipRanks, Klieve is a 4-star analyst with an average return of 3.2% and a 43.40% success rate. Klieve covers the Consumer Defensive sector, focusing on stocks such as Vital Farms, MGP Ingredients, and Lifeway Foods.
Arcadia Biosciences has an analyst consensus of Moderate Buy, with a price target consensus of $12.00.
RKDA market cap is currently $5.88M and has a P/E ratio of -0.83.
Read More on RKDA:
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
